In conclusion, the identification of NU5455 and the preclinical data generated in cancer models suggest that it is possible to achieve an enhanced therapeutic ratio with transient selective pharmacological inhibition of DNA-PKcs in combination with DNA-DSB–inducing therapies. This evidence concerns the gene PRKDC and cancer.